Ionis Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ionis Pharmaceuticals (IONS).

Price Target Range — 7 Quarters

Analyst Consensus — 21 Analysts

1S.Buy

18Buy

2Hold

Consensus RatingBuy# Analysts21Avg. Consensus PT$87Upside to Avg. PT+99.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 22, 2026	BMO Capital	David Lebowitz	Upgrade	Market Perform→Outperform	$54→$66
Oct 15, 2026	UBS	Joon Lee	Upgrade	Neutral→Buy	$46→$88
Sep 24, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$100
Sep 22, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$76→$70
Sep 15, 2026	Guggenheim	Debjit Chattopadhyay	PT Cut	Buy	$89→$80
Sep 9, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$90→$85
Sep 8, 2026	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$110→$104
Sep 8, 2026	Goldman Sachs	Salveen Richter	PT Cut	Neutral	$69→$56
Sep 8, 2026	BMO Capital	David Lebowitz	PT Cut	Market Perform	$61→$54
Sep 8, 2026	Canaccord Genuity	Gary Nachman	PT Cut	Buy	$95→$85
Sep 8, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$115→$100
Sep 4, 2026	Needham	Joseph Stringer	Maintained	Buy	$86
Sep 4, 2026	BMO Capital	David Lebowitz	PT Raise	Market Perform	$60→$61
Sep 4, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$115
Aug 31, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$115
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform→Market Perform	$60
Aug 3, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$72→$76
Jul 30, 2026	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$100→$95
Jul 30, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$125→$115
Jul 21, 2026	Guggenheim	Brad Canino	PT Cut	Buy	$106→$89

Analyst Ratings News

This CME Group Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

Analysts upgraded Ionis, CME Group, DigitalOcean, Prologis and Zions Bancorporation, issuing new or revised price targets.

Avi Kapoor

PRO
BMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66

BMO Capital analyst David Lebowitz upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and raises the price target from $54 to $66.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $100 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70

JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $76 to $70.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80

Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $89 to $80.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85

Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $90 to $85.

Benzinga Newsdesk

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This CME Group Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

PRO
BMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66

PRO
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target

PRO
JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70

PRO
Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80

PRO
Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85

People Also Watch

People Also Watch

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This CME Group Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

PROBMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66

PROHC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target

PROJP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70

PROGuggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80

PROBarclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85

People Also Watch

People Also Watch

PRO
BMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66

PRO
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target

PRO
JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70

PRO
Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80

PRO
Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85